Oruka Therapeutics (NASDAQ:ORKA) Given Outperform Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Friday morning,Benzinga reports. They currently have a $45.00 price target on the stock.

A number of other equities research analysts have also recently weighed in on ORKA. UBS Group assumed coverage on Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $60.00 price objective on shares of Oruka Therapeutics in a report on Friday. Jefferies Financial Group began coverage on Oruka Therapeutics in a research report on Thursday, November 13th. They issued a “buy” rating and a $45.00 target price on the stock. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Finally, Piper Sandler began coverage on Oruka Therapeutics in a research report on Thursday, December 18th. They set an “overweight” rating and a $75.00 price target for the company. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $56.67.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $40.00 on Friday. Oruka Therapeutics has a one year low of $5.49 and a one year high of $41.19. The company has a 50-day simple moving average of $32.92 and a 200-day simple moving average of $27.50. The firm has a market capitalization of $1.94 billion, a P/E ratio of -21.51 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16. As a group, sell-side analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Activity

In related news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the transaction, the insider owned 34,018 shares in the company, valued at $1,101,162.66. This trade represents a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 21,000 shares of company stock valued at $663,530 in the last ninety days. Company insiders own 24.69% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. Goldman Sachs Group Inc. acquired a new position in shares of Oruka Therapeutics during the 1st quarter valued at $2,505,000. Geode Capital Management LLC lifted its holdings in shares of Oruka Therapeutics by 100.6% in the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after buying an additional 354,821 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at $68,000. Intech Investment Management LLC bought a new position in Oruka Therapeutics during the second quarter valued at about $168,000. Finally, JPMorgan Chase & Co. boosted its stake in Oruka Therapeutics by 567.7% during the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after buying an additional 13,115 shares in the last quarter. 56.44% of the stock is owned by institutional investors.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.